Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?

REFERENCES

1. 1.↵
   1. Helliwell PS

   . Verna Wright: father of the spondyloarthropathies. Ann Rheum Dis 2019;78:454–5.

   OpenUrlFREE Full Text
2. 2.↵
   1. Veale DJ,
   2. Fearon U

   . The pathogenesis of psoriatic arthritis. Lancet 2018;391:2273–84.

   OpenUrl
3. 3.↵
   1. Miyagawa I,
   2. Nakayamada S,
   3. Nakano K,
   4. Kubo S,
   5. Iwata S,
   6. Miyazaki Y,
   7. et al.

   Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology 2019;58:336–44.

   OpenUrl
4. 4.↵
   1. Helliwell P,
   2. Coates L,
   3. Chandran V,
   4. Gladman D,
   5. de Wit M,
   6. FitzGerald O,
   7. et al.

   Qualifying unmet needs and improving standards of care in psoriatic arthritis. Arthritis Care Res 2014;66:1759–66.

   OpenUrlCrossRef
5. 5.↵
   1. Scarpa R,
   2. Ayala F,
   3. Caporaso N,
   4. Olivieri I

   . Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006;33:210–2.

   OpenUrlFREE Full Text
6. 6.↵
   1. Manolis AA,
   2. Manolis TA,
   3. Melita H,
   4. Manolis AS

   . Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol 2019;38:33–54.

   OpenUrl
7. 7.↵
   1. Haque N,
   2. Lories RJ,
   3. de Vlam K

   . Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol 2016;43:376–82.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   Webster’s New World Medical Dictionary.Third ed. John Wiley & Sons; 2008.
9. 9.↵
   1. Naredo E,
   2. Möller I,
   3. de Miguel E,
   4. Batlle-Gualda E,
   5. Acebes C,
   6. Brito E,
   7. et al;
   8. Ultrasound school of the Spanish Society of Rheumatology and Spanish ECO-Aps Group

   . High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study. Rheumatology 2011;50:1838–48.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Coates LC,
    2. Lubrano E,
    3. Perrotta FM,
    4. Emery P,
    5. Conaghan PG,
    6. Helliwell PS

    . What should be the primary target of “treat to target” in psoriatic arthritis? J Rheumatol 2019;46:38–42.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Eder L,
    2. Abji F,
    3. Rosen CF,
    4. Chandran V,
    5. Gladman DD

    . The association of obesity and clinical features of psoriatic arthritis: a case-control study. J Rheumatol 2017;44:437–43.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Frasca L,
    2. Palazzo R,
    3. Chimenti MS,
    4. Alivernini S,
    5. Tolusso B,
    6. Bui L,
    7. et al.

    Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: new biomarkers in PsA. Front Immunol 2018;9:1936.

    OpenUrl
13. 13.↵
    1. van Vollenhoven RF,
    2. Hahn BH,
    3. Tsokos GC,
    4. Wagner CL,
    5. Lipsky P,
    6. Touma Z,
    7. et al.

    Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 2018;392:1330–9.

    OpenUrl
14. 14.↵
    1. Ritchlin CT,
    2. Colbert RA,
    3. Gladman DD

    . Psoriatic arthritis. N Engl J Med 2017;376:2095–6.

    OpenUrl
15. 15.↵
    1. Lubrano E,
    2. Perrotta FM

    . Psoriatic arthritis: is it time to treat-to-target or target to treat? Clin Rheumatol 2017;36:2633–5.

    OpenUrl